Principles and Practice of Gastrointestinal Oncology

Hepatocellular cancer screening. Suceveanu Adrian - Referințe bibliografice Google Academic


    hepatocellular cancer screening rectal cancer risk factors

    Lancet Oncol ; 20 8 :Aug. This phase trial evaluated the safety and efficacy of the hafnium oxide HfO2 nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma.

    hepatocellular cancer screening

    Sarc is a phase randomised, multicentre, international trial. Patients had to have a WHO performance status of and a life expectancy of at least 6 months.

    papillon zeugma urlaub cancer and cerebral hemorrhage

    Randomisation was stratified by histological subtype myxoid liposarcoma vs others. This was an open-label study.

    hepatocellular cancer screening parazitii si papiloamele

    The primary endpoint was the proportion of patients with a pathological complete response, assessed by a central pathology review board following Hepatocellular cancer screening Organisation for Research and Treatment of Cancer guidelines in the intention-to-treat population full analysis set. Safety analyses were done in all patients who received at least one puncture and injection of NBTXR3 or at least one dose of radiotherapy.

    This study is registered with ClinicalTrials.

    hpv virus hals symptom

    Two patients in the NBTXR3 group and one patient in the radiotherapy group were excluded from the efficacy analysis because they were subsequently hepatocellular cancer screening to be ineligible; thus, hepatocellular cancer screening total of patients were analysed for the primary endpoint in the intention-to-treat full analysis set 87 in the NBTXR3 group and 89 in the radiotherapy alone group.

    No treatment-related deaths occurred.